CliffBio
small molecule

AMLODIPINE BESYLATE

AMLODIPINE BESYLATE

Loss of exclusivity—loss of exclusivity
CompanySovereign Labs →See this company's full patent-cliff portfolio

Drug detail

Brand nameAMLODIPINE BESYLATE
Active ingredientAMLODIPINE BESYLATE
StrengthEQ 5MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2015
Marketing statusDISCN

More from Sovereign Labs

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.